ABBV Stock: AbbVie Business Overview & Dividend

2026 Update: ABBV Price, Earnings, and Product Growth

For readers asking what ABBV stock is, this guide was updated on October 27, 2026. Market data is through the October 26 close, the latest completed US trading session. AbbVie's latest available financial results at the editorial cutoff were for the quarter ended June 30, 2026. Third-quarter results were scheduled for October 30 and are not estimated here.

ABBV closed at $286.74, with a 52-week range of $190.75 to $291.40 and a market capitalization of approximately $506.7 billion. Yahoo Finance reported trailing EPS of $3.54, a trailing P/E ratio of 81.00, and a five-year monthly beta of 0.23. The indicated annual dividend was $6.92 per share, representing a forward yield of approximately 2.41%.

AbbVie reported Q2 2026 net revenue of $16.990 billion, up 10.2% year over year. GAAP diluted EPS was $2.03, while adjusted diluted EPS was $3.65. Skyrizi and Rinvoq generated combined quarterly revenue of $8.030 billion, compared with $756 million from Humira.

Eligible users can review current market information on the Bybit TradFi ABBV page and, where available, explore ABBV real stock trading. Eligibility, market hours, fees, custody, corporate actions, and shareholder treatment depend on the applicable product terms and jurisdiction.

The article below replaces the former June 2025 market snapshot. Durable explanations of AbbVie's business remain relevant, while outdated prices, dividend yields, product sales, duplicate links, and manual table-of-contents anchors have been removed or updated.

What Is ABBV Stock?

ABBV is the New York Stock Exchange ticker for AbbVie Inc., a global biopharmaceutical company headquartered in North Chicago, Illinois. AbbVie researches, develops, manufactures, and sells medicines across immunology, neuroscience, oncology, aesthetics, and other therapeutic areas.

Buying ABBV shares through a securities account generally gives an investor an ownership interest in AbbVie, subject to the custody arrangements and terms of the broker or platform used. Shareholders may receive declared dividends and voting rights, but neither future dividends nor investment returns are guaranteed.

AbbVie is a member of the S&P 500. Investors using an S&P 500 tracking product therefore already have indirect exposure to ABBV while it remains an index constituent.

AbbVie's History

AbbVie became an independent public company in January 2013 after separating from Abbott Laboratories. The transaction left Abbott focused on areas including medical devices, diagnostics, nutrition, and established medicines, while AbbVie concentrated on research-based pharmaceuticals.

At the time of the separation, AbbVie depended heavily on Humira, a biologic medicine used across several autoimmune diseases. Humira became one of the world's highest-selling medicines, but its success also created major product-concentration and patent-expiry risk.

AbbVie later used acquisitions to broaden its business:

• Allergan in 2020: Added Botox, Juvederm, neuroscience products, eye care, and a global aesthetics business.
• ImmunoGen in 2024: Expanded oncology and added Elahere, an antibody-drug conjugate.
• Cerevel Therapeutics in 2024: Added neuroscience pipeline assets.
• Proposed Apogee Therapeutics acquisition in 2026: Intended to deepen the immunology pipeline; the announced equity value was approximately $10.9 billion.

Acquisitions can add products and research programs, but they also introduce integration costs, debt, intangible assets, clinical risk, and the possibility that projected returns do not materialize.

What Does AbbVie Do?

AbbVie earns revenue by discovering, developing, and commercializing medicines. The process can require years of laboratory work, clinical trials, regulatory review, manufacturing investment, and post-approval safety monitoring.

An approved medicine's commercial value depends on its clinical profile, label, patient population, physician adoption, payer coverage, net pricing, competition, and patent or regulatory exclusivity. Revenue can fall quickly when generic or biosimilar competition begins.

AbbVie groups its products into several major portfolios rather than operating separate reportable business segments in the way an industrial conglomerate might.

AbbVie's Main Products and Portfolios

Immunology

Immunology is AbbVie's largest portfolio. Its key products include:

• Skyrizi: An IL-23 inhibitor used across several immune-mediated conditions.
• Rinvoq: A JAK inhibitor approved for multiple inflammatory diseases.
• Humira: A TNF inhibitor that now faces biosimilar competition.

Q2 2026 immunology revenue was $8.786 billion, up 15.1% year over year. Skyrizi revenue increased 24.4% to $5.505 billion, and Rinvoq rose 24.5% to $2.525 billion. Humira revenue fell 35.9% to $756 million.

Neuroscience

The neuroscience portfolio includes Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev. It covers areas such as psychiatric disorders, migraine, movement disorders, and therapeutic uses of botulinum toxin.

Q2 2026 neuroscience revenue rose 20.3% to $3.228 billion. Vraylar generated $1.071 billion, Botox Therapeutic $1.042 billion, and combined Ubrelvy and Qulipta revenue reached $742 million.

Oncology

AbbVie's oncology products include Venclexta, Imbruvica, Elahere, and Epkinly. Q2 2026 oncology revenue was $1.650 billion, down 1.5% year over year.

Venclexta revenue increased while Imbruvica declined. Elahere continued to grow following the ImmunoGen acquisition. Oncology development remains exposed to trial results, label expansion, competition, safety, and commercial execution.

Aesthetics

Allergan Aesthetics includes Botox Cosmetic, Juvederm, and other products and services. Q2 2026 aesthetics revenue was $1.282 billion, up 0.3% on a reported basis but down 0.9% operationally.

Aesthetics demand can be more sensitive to consumer spending and economic conditions than medically necessary prescription treatments.

Other Established Products

AbbVie also sells medicines in eye care, gastroenterology, virology, and other categories. These products diversify revenue, though some face mature-market competition or declining sales.

The Humira Patent Cliff

A patent cliff occurs when a high-revenue medicine loses exclusivity and lower-priced competition enters. For biologic medicines such as Humira, competitors are called biosimilars rather than traditional small-molecule generics.

US Humira biosimilar competition began in 2023. AbbVie's Humira revenue then declined as competitors gained access and pricing pressure increased.

The key post-Humira question was whether AbbVie could replace the lost revenue. By Q2 2026, Skyrizi and Rinvoq together generated $8.030 billion in one quarter, more than ten times Humira's $756 million. This demonstrates substantial progress, but it also concentrates future expectations in the continued growth and exclusivity of those two medicines.

AbbVie Q2 2026 Financial Overview

AbbVie updated full-year 2026 adjusted diluted EPS guidance to $13.87 to $14.07. The guidance included expected dilution from the proposed Apogee acquisition and year-to-date acquired in-process research and development and milestone expense.

GAAP and adjusted earnings answer different questions. Adjusted figures remove specified items to describe management's view of underlying operations, while GAAP results include recognized accounting expenses. Investors should review the reconciliation rather than substituting one measure for the other without explanation.

ABBV Dividend

AbbVie pays a quarterly cash dividend. At the October 26 market cutoff, the indicated annual amount was $6.92 per share, equivalent to $1.73 per quarter and a forward yield of approximately 2.41% at the closing price.

AbbVie has increased its dividend each year since the 2013 separation. Dividend-growth index treatment also incorporates Abbott's pre-spin history, which is why AbbVie can be included despite having operated independently for fewer years than the index's stated increase requirement.

The dividend yield changes as the share price moves. The older article cited a 3.5% to 4.5% range when ABBV traded at a much lower price; that range should not be presented as current.

Dividend sustainability depends on cash generation, product sales, research spending, debt, acquisitions, tax, and other capital needs. Every future payment remains subject to board approval.

ABBV Stock Valuation

At $286.74, ABBV's trailing P/E ratio was 81.00 based on trailing GAAP EPS of $3.54. The multiple was much higher than the generic low-P/E description in the former article.

AbbVie's GAAP earnings can be reduced by amortization and acquisition-related charges. Adjusted EPS may therefore produce a lower valuation multiple, but investors should keep the definitions consistent. Acquisition costs do not become irrelevant simply because they are excluded from a non-GAAP measure.

Yahoo Finance displayed analyst targets ranging from $200 to $328, with an average of $284.79. ABBV closed slightly above the average target. Price targets are time-sensitive estimates, not guaranteed future prices.

Who Are AbbVie's Competitors?

AbbVie competes at the product and therapeutic-area level rather than against one identical company. Relevant large pharmaceutical peers include Johnson & Johnson, Merck, Bristol Myers Squibb, Eli Lilly, Pfizer, Amgen, and other developers of immunology, oncology, neuroscience, and aesthetics products.

Competition may involve:

• Approved drugs targeting the same disease
• Biosimilars after exclusivity expires
• Clinical-stage treatments that could become a new standard of care
• Pricing and formulary placement with insurers and health systems
• Research talent, acquisition targets, and manufacturing capacity

Peer comparisons should use the same reporting period and distinguish GAAP earnings, adjusted earnings, pipeline assets, patent exposure, debt, and dividend policy.

Risks of Investing in ABBV Stock

Product Concentration

Skyrizi and Rinvoq are large and rapidly growing. That supports current results but makes setbacks affecting either medicine increasingly important.

Patent and Biosimilar Risk

Drug revenue can fall after exclusivity ends. Humira demonstrates how even a leading product can face rapid erosion when competing versions enter.

Clinical and Regulatory Risk

Drug candidates may fail to meet trial endpoints, encounter safety issues, or receive delayed or limited approvals. Approved medicines remain subject to ongoing monitoring and label changes.

Pricing and Reimbursement Risk

Governments, insurers, pharmacy benefit managers, and health systems influence access and net pricing. Rebates and discounts mean list-price changes do not translate directly into revenue.

Acquisition and Balance-Sheet Risk

Large acquisitions require capital and integration. Expected pipeline or sales benefits may arrive later than planned or fail to offset the purchase price.

Litigation and Manufacturing Risk

Pharmaceutical companies face product-liability claims, patent disputes, government investigations, manufacturing interruptions, recalls, and compliance costs.

Valuation Risk

A high share price can embed strong expectations. ABBV could decline even if revenue grows when results fall short of those expectations or the market assigns a lower valuation multiple.

Ways to Gain ABBV Exposure

Investors may obtain exposure through ABBV shares or diversified funds that hold the company. These structures differ in concentration, fees, voting rights, dividend treatment, and tax consequences.

Experienced traders may also review the ABBVUSDT perpetual market, subject to availability. A perpetual contract is a derivative that provides price exposure; it does not represent ownership of AbbVie shares and does not provide dividends, voting rights, or other shareholder rights. Leverage, liquidation, funding payments, basis differences, and rapid price changes can cause substantial losses.

Direct shares and derivative contracts are not interchangeable. Product structure and applicable terms should be reviewed before trading.

Frequently Asked Questions About ABBV Stock

What is ABBV stock?

ABBV is the NYSE ticker for AbbVie Inc., a global biopharmaceutical company based in North Chicago, Illinois.

What was ABBV's stock price in October 2026?

ABBV closed at $286.74 on October 26, 2026. Prices change continuously, so readers should check a current market quote.

What is AbbVie's largest business area?

Immunology is AbbVie's largest portfolio. It generated $8.786 billion of Q2 2026 revenue, led by Skyrizi and Rinvoq.

What happened to Humira?

Humira began facing US biosimilar competition in 2023. Q2 2026 global revenue declined 35.9% year over year to $756 million.

Does ABBV pay a dividend?

Yes. The indicated annual dividend at the October 26 cutoff was $6.92 per share, producing a forward yield of approximately 2.41%. Future dividends are not guaranteed.

Is AbbVie still dependent on Humira?

Humira is now much smaller than Skyrizi and Rinvoq. AbbVie has diversified, but the company remains dependent on successful medicines and increasingly on its two major immunology growth products.

Is an ABBV perpetual the same as owning ABBV stock?

No. A perpetual is a derivative linked to price movement. It does not confer share ownership, dividends, voting rights, or other shareholder rights.

Conclusion

ABBV represents ownership in AbbVie, a large pharmaceutical company that has moved beyond its former dependence on Humira. Skyrizi and Rinvoq now drive immunology growth, while neuroscience, oncology, aesthetics, established products, and acquisitions broaden the business.

The Q2 2026 results showed strong revenue and adjusted EPS growth, but the investment case still depends on product safety, exclusivity, reimbursement, clinical execution, acquisition returns, cash flow, and valuation. The dividend adds an income component without eliminating these risks.

Sources and cutoffs: Market price, range, market capitalization, beta, valuation, dividend, and analyst targets are from Yahoo Finance ABBV through October 26, 2026. Financial, portfolio, and guidance data are from AbbVie's Q2 2026 financial results, published July 31, 2026. Q3 results were scheduled for October 30 and were not available at the October 27 editorial cutoff.

Disclaimer: This article is for informational and educational purposes only. It is not financial, investment, legal, tax, medical, or trading advice. Investing in stocks or derivatives can result in loss.